Acasti Pharma Comprehensive Income 2014-2024 | GRCE

Acasti Pharma comprehensive income from 2014 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Acasti Pharma Annual Comprehensive Income
(Millions of US $)
2024 $-6
2023 $-6
2022 $-6
2021 $-6
2020 $-8
2019 $-7
2018 $
2017 $
2016 $
2015 $
2015 $
2014 $
2014 $
2013 $
2013 $
Acasti Pharma Quarterly Comprehensive Income
(Millions of US $)
2024-06-30 $-6
2024-03-31 $-6
2023-12-31 $-6
2023-09-30 $-6
2023-06-30 $-6
2023-03-31 $-6
2022-12-31 $-6
2022-09-30 $-6
2022-06-30 $-6
2022-03-31 $-6
2021-12-31 $-7
2021-09-30 $-7
2021-06-30 $-6
2021-03-31 $-6
2020-12-31 $-7
2020-09-30 $-7
2020-06-30 $-8
2020-03-31 $-8
2019-12-31
2019-09-30
2019-06-30
2019-03-31 $-7
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-02-28
2016-11-30
2016-08-31
2016-05-31
2016-03-31
2016-02-29
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2014-02-28
2013-12-31
2013-09-30
2013-06-30
2013-03-31
Sector Industry Market Cap Revenue
Medical MED-GENERIC DRG $0.033B $0.000B
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Stock Name Country Market Cap PE Ratio
Merck (MKKGY) Germany $21.306B 23.25
New York Community Bancorp (FLG) United States $4.269B 0.00